Current Headlines

  1. Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP

    Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all

  2. Incyte Announces Top-Line Results From RELIEF Trial Of Ruxolitinib In Patients With Polycythemia Vera

    Incyte Corporation recently announced top-line results from RELIEF, a randomized, double-blind clinical trial designed to compare symptom improvement in 110 patients with polycythemia vera (PV) treated with ruxolitinib versus patients treated with hydroxyurea (HU)

  3. Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program

    Humacyte, Inc., a pioneer in regenerative medicine, has announced that the U.S. Food and Drug Administration (FDA) has designated the HumaGraft development program for vascular access in hemodialysis patients as a Fast Track Development Program

  4. Genocea Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy

    Genocea Biosciences, Inc. a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, recently announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2)

  5. Exploring The Challenges In Drug Delivering System For Efficient Solutions

    Although OMICS Group focused in the year 2011-2014 on exploring the novel research in the field of Pharmaceutics and NDDS, it spared the year 2015 to share international experiences with the world leaders from Pharmaceutical and Bio Pharmaceutical Research diverting a major section of research to focus on formulating a variety of poorly soluble and highly unstable substances, reporting it to be the significant arena in pharmaceutical research

  6. Regulus Receives Orphan Drug Designation For RG-012, A microRNA Therapeutic For The Treatment Of Alport Syndrome

    Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"), as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy

  7. MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. To Develop Small Molecules Targeting Sarcopenia And Cachexia

    MYOS Corporation("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research and development agreement with Cloud Pharmaceuticals, Inc

  8. La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)

    La Jolla Pharmaceutical Company (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases,recently announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial

  9. Compugen Extends Discovery Capabilities To Additional Immunomodulatory Proteins

    Compugen Ltd. recently announced the extension of its predictive discovery capability to identify immunomodulatory proteins in addition to the B7/CD28-like proteins that have been the focus of the Company’s Pipeline Program to date. The initial utilization of this extended capability resulted in the discovery of four novel immunomodulatory proteins predicted to act as immune checkpoints

  10. PTC Therapeutics Announces Expanded Access Program For Translarna™ (Ataluren)

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna™ (ataluren) available to patients before commercial availability in certain countries

Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers